The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | N | Nervous system | |
2 | N02 | Analgesics | |
3 | N02A | Opioids | |
4 | N02AX | Other opioids |
Code | Title | |
---|---|---|
N02AX01 | Tilidine | |
N02AX02 | Tramadol | |
N02AX03 | Dezocine | |
N02AX05 | ||
N02AX06 | ||
N02AX07 | ||
N02AX51 |
Active Ingredient | Description | |
---|---|---|
Meptazinol |
Meptazinol is a centrally acting analgesic belonging to the hexahydroazepine series, which has demonstrated mixed agonist and antagonist activity at opioid receptors. It is used for the short term treatment of moderate pain. |
|
Tapentadol |
Tapentadol is a strong analgesic with µ-agonistic opioid and additional noradrenaline reuptake inhibition properties. Tapentadol exerts its analgesic effects directly without a pharmacologically active metabolite. |
|
Tilidine |
Tilidine is a synthetic opioid painkiller, for the treatment of moderate to severe pain, both acute and chronic. Tilidine itself is only a weak opioid, but is rapidly metabolised in the liver and gut to its active metabolite nortilidine and then to bisnortilidine. It is the (1S,2R)-isomer (dextilidine)12 that is responsible for its analgesic activity. Nortilidine binds to opiate receptors in the central and peripheral nervous systems and suppresses pain perception and transmission. |
|
Tramadol |
Tramadol is a centrally acting opioid analgesic. It is a non selective pure agonist at μ-, δ- and κ-opioid receptors with a higher affinity for the μ-receptor. Other mechanisms which may contribute to its analgesic effect are inhibition of neuronal reuptake of noradrenaline and enhancement of serotonin release. Tramadol has an antitussive effect. In contrast to morphine, analgesic doses of tramadol over a wide range have no respiratory depressant effect. |
Title | Information Source | Document Type | |
---|---|---|---|
DOLTREX Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
MEPTID Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
MEPTID Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
NUCYNTA ER Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
PALEXIA Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
PALEXIA Oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
PALEXIA SR Prolonged-release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
TRAMAL Capsule, Solution for injection, Tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
ULTRAM Coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
ZYDOL Soluble tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ZYDOL Solution for injection or infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ZYTRAM XL Controlled release tablet | Health Products and Food Branch (CA) | MPI, CA: SPM |